OverviewSuggest Edit

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 7500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules and no major patient expiration in the next decade; - More than 25% of 2015 revenue reinvested into Research & Development - 2015 Key Financials: €3.88B global revenue Specialties: Neurology, Immunology
TypePublic
Founded1928
HQAnderlecht, BE
Websiteucb.com
Employee Ratings4
Overall CultureC

Latest Updates

Employees (est.) (Dec 2020)8,371(+11%)
Job Openings342
Share Price (Jun 2021)€82.9
Cybersecurity ratingCMore

Key People/Management at UCB

Antje Witte

Antje Witte

VP, Investor Relations
Jean-Christophe Tellier

Jean-Christophe Tellier

Chief Executive Officer & Chairman of the Executive Committee
Isabelle Ghellynck

Isabelle Ghellynck

Associate Director, Investor Relations
Alice Dautry

Alice Dautry

Independent Director
Kirsten Lund-Jurgensen

Kirsten Lund-Jurgensen

Executive Vice President, Supply & Technology Solutions
Jan Berger

Jan Berger

Independent Director
Show more

UCB Office Locations

UCB has offices in Anderlecht, Braine-l'Alleud, København, Esbo and in 7 other locations
Anderlecht, BE (HQ)
60 Allée de la Recherche
Braine-l'Alleud, BE
Avenue de l'Industrie
Braine-l'Alleud, BE
Chemin du Foriest
København, DK
Edvard Thomsens Vej 14, 7 th floor
Esbo, FI
Bertel Jungs plats 5 6th floor
Almaty, KZ
21, Tole Bi Street 69
Show all (14)

UCB Financials and Metrics

UCB Revenue

Market capitalization (11-Jun-2021)

15.7b

Closing stock price (11-Jun-2021)

82.9
UCB's current market capitalization is €15.7 b.
Show all financial metrics

UCB Operating Metrics

FY, 2015FY, 2016

Patients Reached

1.85 m2.59 m
Show all operating metrics

UCB Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

UCB Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

UCB Online and Social Media Presence

Embed Graph

UCB Company Culture

  • Overall Culture

    C

    66/100

  • CEO Rating

    F

    35/100

  • Compensation

    A+

    100/100

Learn more on Comparably

UCB News and Updates

Global Parkinson's Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis

Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering. The global PD market is forecast to experience significant growth during the forecast period; global sales are expecte…

UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio

BRUSSELS and ATLANTA, April 16, 2021 /PRNewswire/ -- UCB is pleased to announce that new data representing three neurological areas will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting, from 17-22 April 2021.1-9 Spanning across epilepsy and Parkinson's disease,...

UCB SA/NV - Convening notice annual shareholders meeting

*** Unofficial English translation – For convenience purposes only ***

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future

BRUSSELS, Feb. 25, 2021 /PRNewswire/ -- "We are very impressed by our employees and partners for their resilience and achievements during 2020. Together we continued to serve patients, took good care of each other and joined forces in the global response to COVID-19. 2020 was another year...

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

BRUSSELS and ATLANTA, Feb. 23, 2021 /PRNewswire/ -- Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology Microsoft will provide AI technology and applied scientists to work...

Global Anti-Parkinson Drugs Market Report 2020-2030: Major Players are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc. and Mylan

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Anti-Parkinson Drugs Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Anti-Parkinson Drugs Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists,...
Show more

UCB Blogs

Our Commitment to Changing the Status Quo in Psoriasis Care

Posted by Susanne Farwer, Immunology BII.

UCB @ AOEC 2021: our commitment to women of childbearing age living with epilepsy

Posted by Konrad Werhahn, Global Epilepsy Strategy.

UCB Celebrates Patient Strength During MG Awareness Month

Posted by Donatello Crocetta, UCB Rare Disease Organization.

Clinical Trial Day: Honoring our Clinical Researchers

Posted by Becky Malone, Patient Value Development Solutions.

Why UCB has made a science-based commitment to reducing emissions

Posted by Anne-Laure Demarcy, Global Health, Safety & Environment.
Show more

UCB Frequently Asked Questions

  • When was UCB founded?

    UCB was founded in 1928.

  • Who are UCB key executives?

    UCB's key executives are Antje Witte, Jean-Christophe Tellier and Isabelle Ghellynck.

  • How many employees does UCB have?

    UCB has 8,371 employees.

  • Who are UCB competitors?

    Competitors of UCB include Genewiz, Laboratorios Bago and Indena.

  • Where is UCB headquarters?

    UCB headquarters is located at 60 Allée de la Recherche, Anderlecht.

  • Where are UCB offices?

    UCB has offices in Anderlecht, Braine-l'Alleud, København, Esbo and in 7 other locations.

  • How many offices does UCB have?

    UCB has 14 offices.